slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 216,691-216,720
Pages 10,126
Rows per page 30
Component
216,691-216,720 of 303,780
14
The table lists various non-cash and non-recurring items added back to net income.Nexters | Results Presentation Deck | 14 slides · GDEV Inc.
Conference presentation Investor relations 1 hit
01
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
02
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
04
The chart uses a horizontal bar format to represent clinical trial progression stages.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
05
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
06
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Beat · Problem1 hit
08
DED stands for Dry Eye Disease.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
The slide features a molecular structure illustration of the lipid-conjugated peptide.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
10
The slide uses a numbered process diagram to illustrate the biological mechanism of the drug candidate OK-101.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
11
The slide depicts a molecular mechanism of action (MOA) for a pharmaceutical compound.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
12
The slide uses two dose-response curves to illustrate the efficacy of membrane anchoring.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Loop · Before After1 hit
13
The chart shows that OK-101 (0.04%) reduces corneal permeability to levels comparable to Cyclosporine (0.1%) and significantly better than the phosphate buffer control.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Loop · Before After1 hit
14
Data source: Patil et al. (2019).OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Loop · Before After1 hit
15
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Beat · Agitate1 hit
16
The slide uses a diagram to explain the surgical model and a bar chart to show the comparative efficacy results over 14 days.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Beat · Agitate1 hit
17
The slide uses a circular diagram to represent the 'Dry Eye Cycle' and overlays the drug's mechanism of action as an intervention.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations Beat · Solution1 hit
18
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
19
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
20
The slide uses a process-flow diagram to illustrate the 3-arm study structure.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
21
PTA refers to Patent Term Adjustment.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
23
The slide uses a split-column layout to distinguish between Management and Board members, accompanied by logos of relevant past/current affiliations.OKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
24
OKYO Pharma | Results Presentation Deck | 25 slidesOKYO Pharma | Results Presentation Deck | 25 slides · OKYO Pharma
Conference presentation Investor relations 1 hit
03
Orbia | Investor Presentation Deck | 62 slidesOrbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Situation & Context1 hit
04
Orbia | Investor Presentation Deck | 62 slidesOrbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Situation & Context1 hit
05
Orbia | Investor Presentation Deck | 62 slidesOrbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Situation & Context1 hit
08
The slide uses a bar chart to show performance trends and a circular diagram to illustrate the pillars of their safety strategy.Orbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
09
Includes a world map highlighting strategic hubs and a donut chart showing revenue distribution by region.Orbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
14
Includes logos for Vestolit and Alphagary.Orbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Solution & Approach1 hit
16
The slide outlines a capital investment project with specific financial metrics ($650M EBITDA, 4x multiple) and a timeline (2024-2028).Orbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
21
Includes Netafim branding and financial metrics for 2022.Orbia | Investor Presentation Deck | 62 slides · Orbia
Conference presentation Investor relations Beat · Solution & Approach1 hit